Background
==========

Reviewers and users of reviews draw conclusions about the overall quality of the evidence that is reviewed. Similarly, people making recommendations and users of those recommendations draw conclusions about the strength of the recommendations that are made. Systematic approaches to doing this can help protect against errors by both doers and users, and can facilitate critical appraisal and communication of the conclusions that are made.

The GRADE Working Group began as an informal collaboration of people with an interest in addressing shortcomings in systems for grading evidence and recommendations. We report elsewhere a critical appraisal of six prominent systems for grading evidence and recommendations \[[@B1]\]. Based on this critical appraisal and a series of discussions, we reached agreement on the key attributes of a system that would address the major shortcomings that we identified. Based on the critical assessment of existing approaches, the agreement we had reached about the key elements that should be included in an approach for grading the level of evidence and strength of recommendations and our previous experiences we put together a suggestion for a grading system. We then applied the suggested system to a series of examples and discussed and revised the system based on this experience and the consideration of other examples. Examples were selected to challenge our thinking. All of the examples used in this pilot study were questions about interventions. We describe here the pilot study of this system.

The aims of the pilot study were to test whether the approach is sensible relative to diverse examples of evidence and recommendations, and to agree on necessary changes to the approach, decision rules, and changes in how the evidence profiles used in the pilot study were constructed. The revised approach is described elsewhere \[[@B16]\].

Methods
=======

Seventeen people independently judged the quality of evidence, the balance between benefits and harms, and the formulation of a recommendation for 12 examples. The 17 judges all had experience using other approaches to grade evidence and recommendations.

Evidence profiles
-----------------

For each example we prepared an evidence profile. Each evidence profile was made based on information available in a systematic review and consists of two tables, one for quality assessment of the available information and one table that presents a summary of the findings (Table [1](#T1){ref-type="table"} and Table [2](#T2){ref-type="table"}). For the purpose of testing our grading approach in this pilot study we made the assumption that the systematic reviews that we used were all well conducted. The examples we used and presented here were selected to test our new approach, not with an intention of making actual recommendations for a specific setting based on up-to-date systematic reviews. The quality assessment table was designed such that the quality of each outcome was evaluated separately. For each outcome, the table contained information regarding the number of studies that had reported the outcome, information about the study design (RCTs or observational studies) and the quality of the studies that reported on that outcome (was there any limitations in the design or conduct of these studies). Also included in the quality assessment table was information about the consistency of the results across studies for each outcome and information regarding directness of the study population, outcome measure, intervention and comparison. The summary of findings table was also designed such that each outcome was presented separately. For each outcome information are presented about both the experimental and the control group patients, for dichotomous outcomes the number of events and the total number of participants, and for continuous outcomes means (standard deviation) and the number of patients were presented. Also included in the summary of findings table is information about the effect, relative effect (95% confidence interval) and absolute effect for each outcome.

###### 

Example of an evidence profile quality assessment given to the evaluators for them to grade in the pilot study. Example question: Should depressed patients in primary care be treated with SSRIs rather than tricyclics?

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome: **Depression severity**(measured with Hamilton Depression Rating Scale)                                                                                                             
  ---------------------------------------------------------------------------------- ------------------------------------------ --------------------------------- ---------------------------- ----------------------------------------------------
  Studies                                                                            Design                                     Quality                           Consistency                  Directness

                                                                                                                                                                                               

  8 trials Citalopram\                                                               RCTs                                       No serious flaws                  No important inconsistency   Some uncertainty about relevance (outcome measure)
  38 trials Fluoxetine\                                                                                                                                                                        
  25 trials Fluvoxamine\                                                                                                                                                                       
  2 trials Nefazodone\                                                                                                                                                                         
  18 trials Paroxetine\                                                                                                                                                                        
  4 trials Sertaline\                                                                                                                                                                          
  4 trials Velafaxine                                                                                                                                                                          

                                                                                                                                                                                               

  Outcome: **Transient side effects**(drop-out from 6 week treatment)                                                                                                                          

                                                                                                                                                                                               

  8 trials Citalopram\                                                               RCTs                                       No serious flaws                  No important inconsistency   Some uncertainty about relevance (outcome measure)
  50 trials Fluoxetine\                                                                                                                                                                        
  27 trials Fluvoxamine\                                                                                                                                                                       
  4 trials Nefazodone\                                                                                                                                                                         
  23 trials Paroxetine\                                                                                                                                                                        
  6 trials Sertaline\                                                                                                                                                                          
  5 trials Velafaxine                                                                                                                                                                          

                                                                                                                                                                                               

  Outcome: **Poisoning fatalities**                                                                                                                                                            

                                                                                                                                                                                               

  Office for National Statistics (British)                                           Observational data (national statistics)   Serious flaw, population based\   Only one study               Direct
                                                                                                                                Reporting bias                                                 
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Example of an evidence profile summary of findings given to the evaluators for them to grade in the pilot study. Example question: Should depressed patients in primary care be treated with SSRIs rather than tricyclics?

  **Outcome**              SSRI                              tricyclics                         Effect                        Quality         Relative importance   
  ------------------------ --------------------------------- ---------------------------------- ----------------------------- --------------- --------------------- --
  Depression Severity      5044 patients                     4510 patients                      WMD 0.034 (-0.007 to 0.075)   No difference                         
  Transient side effects   1948/7032 (28%)                   2072/6334 (33%)                    RRR 13% (5% to 20%)           20                                    
  Poisoning fatalities\*   1/100,000 per year of treatment   58/100,000 per year of treatment   RRR 98%                       1754                                  

\* Uncertainty about baseline risk: Fatality data may be influenced by which pills are given to whom, and it is uncertain if changing antidepressant would deter suicide attempts

Instructions and a form for recording each judgement were included with each example \[see [Additional file 1](#S1){ref-type="supplementary-material"}\]. The judges were instructed to apply the approach without second guessing the information presented in the evidence profile or the approach. They were asked to note problems that they encountered and judgements that did not make sense to them when they adhered to the approach as instructed.

Questions and judgements
------------------------

The 12 examples were selected to include a variety of health care interventions, types of evidence and types of recommendations. The questions that were posed in the 12 examples were:

• Should depressed patients in primary care be treated with SSRIs or tricyclics? \[[@B2]\]

• Should patients with atrial fibrillation be treated with warfarin or aspirin for prevention of stroke? \[[@B3]\]

• Should patients with pain believed to be due to degenerative arthritis be treated with non-steroidal anti-inflammatory drugs (NSAIDs) or paracetamol? \[[@B4]\]

• Should patients who have had a myocardial infarction be given antiplatelet therapy to reduce all cause mortality? \[[@B5]\]

• Should patients who have had a myocardial infarction be offered exercise rehabilitation? \[[@B5]\]

• Should patients with deep venous thrombosis be treated with Low Molecular Weight Heparin (LMWH) or IV unfractionated heparin for prevention of pulmonary embolism? \[[@B6]\]

• Should antibiotics be used to treat acute maxillary sinusitis? \[[@B7]\]

• Should BCG vaccine be used to prevent tuberculosis? \[[@B8]\]

• Should surgical discectomy be recommended for patients with sciatica due to lumbar disc prolapse? \[[@B9]\]

• Should community water fluoridation be used to reduce dental caries? \[[@B10],[@B11]\]

• Should distribution of child safety seats and education programs be used to increase correct use of child safety seats? \[[@B12]\]

• Should hormone replacement therapy be given to prevent cardiovascular heart disease in healthy post menopausal women? \[[@B13]\]

For each example each person made judgements about;

• the quality of evidence for each outcome, scored as high, intermediate, low, or very low;

• the relative importance of each outcome, scored as critical to the decision (7--9), important but not critical to the decision (4--6), or not important to the decision (1--3);

• the overall quality of all the critical outcomes, scored as high, intermediate, low, or very low;

• the balance between benefits and harms, scored as net benefit, trade offs, uncertain net benefit, or not net benefit; and

• the recommendation, scored as do it, probably do it, toss up, probably don\'t do it, or don\'t do it.

For each example the judgements made by all 17 people were collected and summarised as illustrated in Table [3](#T3){ref-type="table"}. Disagreements were discussed at a meeting attended by 15 of the 17 judges. Because of a lack of time, the last two examples were discussed at another meeting attended by six of the 17 judges, but all 17 raters provided judgements for all of the 12 examples. For each example the kappa agreement was calculated \[[@B14]\] for the 17 graders across the four levels for the quality of evidence across outcomes for each example (number of outcomes per example range from two to seven), across all outcomes (46) and for the judgements about overall quality of the evidence (12).

###### 

Summary of the judgements made by the 17 evaluators for Example 1 of the pilot study. Should depressed patients in primary care be treated with SSRIs rather than tricyclics?

  Rater   Quality of outcome                                                    Relative importance of outcome                                                   Overall quality   Balance benefits vs harm   Recommendation
  ------- --------------------- ------------------------ ---------------------- -------------------------------- ------------------------ ---------------------- ----------------- -------------------------- ----------------
          Depression severity   Transient side effects   Poisining fatalities   Depression severity              Transient side effects   Poisining fatalities                                                
                                                                                                                                                                                                              
  1       H                     H                        Vl                     7                                9                        9                      H or Vl           Uncertain net benefit      Don\'t do it
  2       M                     M                        Vl                     9                                6                        7                      Vl                Net benefit                Probably do it
  3       H                     H                        M                      8                                7                        9                      H                 Uncertain net benefit      Toss up
  4       H                     H                        L                      6                                5                        6                                                                   
  5       M                     M                        M                      9                                6                        8                      M                 Net benefit                Do it
  6       M                     M                        Vl                     9                                6                        9                      Vl                Net benefit                Do it
  7       M                     M                        L                      8                                7                        8                      L                 Net benefit                Do it
  8       H                     H                        Vl                     9                                5                        3                      H                 Net benefit                Probably do it
  9       M                     M                        L                      9                                6                        8                      L                 Net benefit                Probably do it
  10      M                     M                        L                      9                                7                        8                      L                 Net benefit                Probably do it
  11      H                     H                        L                      8                                5                        7                      L                 Trade offs                 Probably do it
  12      H                     H                        L                      8                                5                        7                      L                 Trade offs                 Probably do it
  13      M                     H                        M                      9                                7                        9                      M                 Net benefit                Do it
  14      M                     M                        L                      9                                9                        5 OR 9                 M                 Net benefit                Probably do it
  15      M                     M                        Vl                     9                                6                        8                      Vl                Uncertain net benefit      Toss up
  16      M                     M                        Vl                     9                                5                        9                      Vl                Not net benefit            Don\'t do it
  17      M                     M                        M                      9                                9                        9                      M                 Net benefit                Toss up

Sensibility and understandability
---------------------------------

After grading all 12 examples, the judges were asked 16 questions regarding the sensibility and understandability of the approach. Each question consisted of a statement and five response options: strongly disagree, disagree, not sure, agree, and strongly agree. Eleven people completed this questionnaire. The questionnaire was adapted from Feinstein \[[@B15]\] and the 16 statements were:

1\. The approach is applicable to different types of interventions, including drugs, surgery, counselling, and community-based interventions.

2\. The approach is clear and simple to apply

3\. The information that is needed is generally available.

4\. Subjective decisions are generally not needed.

5\. All of the components included in each of the five types of judgements should be included

6\. There are not important components that are missing for any of the five types of judgements.

7\. The ways in which the components are aggregated for each of the five types of judgements are clear and simple.

8\. The ways in which the included components are aggregated are appropriate for each of the five types of judgements.

9\. The categories are sufficient to discriminate between different grades for each of the five types of judgements.

10\. The approach successfully discriminates between different grades of evidence.

11\. The approach successfully discriminates between different grades of recommendations.

12\. The overall quality of evidence is clear and understandable.

13\. The balance between the benefits and harms is clear and understandable.

14\. The recommendation is clear and understandable.

15\. The way in which the overall quality of evidence was graded is better than other ways of doing this with which I am familiar.

16\. The way in which the recommendation was graded is better than other ways of doing this with which I am familiar.

Results
=======

Quality of evidence for each outcome
------------------------------------

The quality of evidence for each outcome as assessed by the 17 graders are shown in Table [4](#T4){ref-type="table"}. Much of the disagreement was due to lacking information in the evidence summaries that we prepared based on the information available in the chosen examples. We agreed that the evidence summaries should include footnotes explaining the basis for judgements about study quality, consistency and directness. We also agreed that it was necessary to include information about baseline risk and the setting as part of the background information since different assumptions about these factors also explained some of the disagreement. It was possible to reach a consensus about the quality of evidence for most outcomes when we discussed our judgements. Of the 48 outcomes that were included across the 12 examples, we were not able to reach a consensus regarding five. The lack of consensus resulted from disagreement about whether there was sparse data for three outcomes and because of insufficient information for two outcomes.

###### 

Results, summary of the judgements made by the 17 evaluators of the quality for each of the outcomes presented in the 12 examples in the pilot study.

  Outcome                         High    Moderate   Low     Very low   Consensus   Comments
  ------------------------------- ------- ---------- ------- ---------- ----------- -------------------------------------------------
  Depression severity             6/17    10/17      \-      \-         Moderate    
  Transient side effects          7/17    10/17      \-      \-         High        Changed to little uncertainty
  Poisoning fatalities            \-      4/17       7/17    6/17       Moderate    Upgraded for very strong association
  Stroke                          15/17   2/17       \-      \-         High        
  Extracranial hemorrage          16/16   \-         \-      \-         High        
  All cause mortality             12/17   5/17       \-      \-         \-          Agreed to remove this outcome
  Pain at rest                    16/17   1/17       \-      \-         High        
  Pain ay motion                  15/17   2/17       \-      \-         Moderate    Uncertainty about directness of outcome measure
  Mobility                        3/17    14/17      \-      \-         Moderate    
  Quality of life                 1/17    11/17      5/17    \-         Moderate    
  Dropout due to side effects     14/17   3/17       \-      \-         High        
  Serious gi complications        \-      3/17       8/17    6/17       \-          Need more information before consensus
  All cause mortality             2/17    15/17      \-      \-         Moderate    
  Non-fatal stroke                17/17   \-         \-      \-         High        
  Non-fatal MI                    17/17   \-         \-      \-         High        
  Death                           13/17   4/17       \-      \-         High        
  Non-fatal MI                    11/16   5/16       \-      \-         High        
  All cause death                 12/17   5/17       \-      \-         Moderate    If reporting bias, otherwise high
  Major bleeding                  15/17   2/17       \-      \-         High        
  Recurrent thromboembolism       6/17    11/17      \-      \-         High        
  Clinical cure                   \-      13/17      4/17    \-         Moderate    
  Dropout due to side effects     \-      10/17      7/17    \-         Moderate    
  Relapse                         2/17    11/17      4/17    \-         Moderate    
  Tuberculosis                    2/17    10/17      5/17    \-         Moderate    
  TB death                        8/17    8/17       1/17    \-         High        
  TB meningitis                   1/17    4/17       12/17   \-         Moderate    Strong association
  Serious adverse events          1/12    \-         \-      11/12      \-          No data, outcome removed
  Condition unchanged             5/17    19/17      2/17    \-         \-          No consensus regarding sparse data
  Poor outcome- surgeon rated     9/17    8/17       \-      \-         \-          Need bias information before consensus
  2^nd^procedure needed           9/17    8/17       \-      \-         Moderate    
  No success -- objective rater   5/17    10/17      2/17    \-         \-          No consensus regarding sparse data
  Risks & side effects            1/15    2/15       2/15    10/15      \-          No data, outcome removed
  Dental caries -- start          \-      \-         8/17    9/17       Very low    
  Dental caries -- stop           \-      \-         5/17    12/17      Very low    
  Dental florosis                 \-      1/17       3/17    13/17      Very low    
  Bone fracture                   \-      1/17       3/17    13/17      Very low    
  Cancer mortality                \-      1/17       2/17    14/17      Very low    
  All injuries                    \-      1/17       12/17   4/17       Very low    Question changed
  Correct use early               8/17    5/17       4/17    \-         High        Question changed
  Correct use follow up           2/17    8/17       6/17    1/17       High        Question changed
  Possession of seat              7/17    6/17       3/17    \-         High        Question changed
  CHD                             11/13   2/13       \-      \-         High        
  Breast cancer                   11/13   2/13       \-      \-         High        
  Stroke                          11/13   2/13       \-      \-         High        
  Colorectal cancer               11/13   2/13       \-      \-         High        
  Endometrial cancer              11/13   2/13       \-      \-         High        
  Hip fracture                    11/13   2/13       \-      \-         High        

We found that in addition to study design, quality, consistency and directness, other quality criteria also influenced judgements about evidence. These additional criteria were sparse data, strong associations, publication bias, dose response, and situations where all plausible confounders strengthened rather than weakened our confidence in the direction of the effect. Concequently, the consistency with which we considered these additional issues were affected and disagreements regarding the quality of evidence for each outcome were reduced.

Relative importance of each outcome
-----------------------------------

Specification of outcomes in the question that each example addressed resulted in some confusion regarding the relative importance of each outcome and the overall quality of evidence across outcomes. We therefore agreed that outcomes should not be included in the questions and that all important outcomes should be considered. There was good agreement about the relative importance of the 48 outcomes that were considered. We reached a consensus about the relative importance of all but two of the outcomes. This was due to uncertainty and true disagreement about the importance of these two outcomes, dental fluorosis and bone fractures, in relation to the question about water fluoridation.

Overall quality of important outcomes
-------------------------------------

There was a lack of agreement about the overall quality of evidence across the critical outcomes for each question (Table [5](#T5){ref-type="table"}). This poor agreement reflected an accumulation of disagreements about the quality of evidence and importance of the individual outcomes that were considered for each question. In addition, we found that it did not make sense to downgrade the overall quality of evidence because of lower quality evidence for one of several critical outcomes when all of the outcomes showed effect in the same direction. We therefore agreed that the overall quality of evidence should be based on the higher quality evidence, rather than the lowest quality of evidence, when all of the results are in favour of the same option.

###### 

Results, summary of the judgements made by the 17 evaluators of the overall quality in the 12 examples in the pilot study

  **Example**   **High**   **Moderate**   **Low**   **Very low**   **Consensus**                                      **Comments**
  ------------- ---------- -------------- --------- -------------- -------------------------------------------------- -----------------------
  1             2/15       4/15           5/15      4/15           Moderate                                           
  2             12/17      5/17           \-        \-             High                                               
  3             1/17       6/17           5/17      5/17           Need more information before consensus             
  4             4/17       13/17          \-        \-             High                                               Based on the new rule
  5             12/16      4/16           \-        \-             High                                               
  6             7/17       10/17          \-        \-             High                                               Based on new rule
  7             \-         11/17          6/17      \-             Moderate                                           
  8             \-         6/17           3/17      8/17           High                                               Based on new rule
  9             2/16       3/16           5/16      6/16           High/Moderate depending if there are fatal flaws   
  10            \-         1/17           4/17      12/17          Very low                                           
  11            1/17       3/17           8/17      5/17           High                                               Changed question
  12            11/13      2/13           \-        \-             High                                               

The kappa statistics for each question are shown in Table [6](#T6){ref-type="table"}. The number of outcomes per example range from two to seven and the kappa ranged from 0 to 0.82. In some instances, the agreement among the graders was slightly worse than by chance as indicated by the negative kappa values seen in Table [6](#T6){ref-type="table"}. The kappa across the 46 outcomes included in the calculation was 0.395 (SE 0.008). Kappa for agreement beyond chance for the 12 final judgements about the quality of evidence was 0.270 (SE 0.015).

###### 

Results, kappa agreement among the evaluators for each of the 12 examples in the pilot study

  **Example**   **No of outcomes**   **P**   **Kappa**   **(SE)**
  ------------- -------------------- ------- ----------- ----------
  1             3                    0.436   0.149       0.031
  2             3                    0.769   0.075       0.053
  3             6                    0.643   0.441       0.024
  4             3                    0.926   0.823       0.050
  5             2                    0.608   -0.044      0.065
  6             3                    0.618   0.163       0.050
  7             3                    0.520   -0.028      0.044
  8             3                    0.451   0.146       0.036
  9             4                    0.441   -0.022      0.037
  10            5                    0.579   0.005       0.034
  11            4                    0.377   0.112       0.027
  12            7                    0.718   -0.083      0.043

Balance between benefits and harms
----------------------------------

The graders assessments about the balance between benefits and harms are shown in Table [7](#T7){ref-type="table"}. There is visibly a poor agreement, this can, in part, be explained by the accumulation of all the previous differences in grading of the quality and importance of the evidence. Some of the judges made assumptions or considered information that was not included in the evidence profiles. When we discussed these judgements, we reached a consensus about the balance between benefits and harms for all but three questions. For one question we found we needed more information. For the second judgement we disagreed about the importance of two of the outcomes. For the third judgement we disagreed about the relative values we attached to the benefits and the harms.

###### 

Results, summary of the judgements made by the 17 evaluators about the balance between benefits and harms for each of the 12 examples in the pilot study

  Example   Net benefit   Trade offs   Uncertain net benefits   Not net benefits   Consensus
  --------- ------------- ------------ ------------------------ ------------------ ------------------------------
  1         10/16         2/16         3/16                     1/16               Net benefit
  2         11/16         4/16         1/16                     \-                 Net benefit
  3         2/17          8/17         7/17                     \-                 Need more information
  4         15/16         \-           1/16                     \-                 Net benefit
  5         13/17         \-           4/17                     \-                 Net benefit
  6         13/17         2/17         2/17                     \-                 Net benefit
  7         4/17          3/17         9/17                     1/17               Uncertain net benefits
  8         7/16          \-           9/16                     \-                 Net benefit
  9         2/16          8/16         6/16                     \-                 Uncertain benefit/trade offs
  10        2/17          4/17         10/17                    1/17               No consensus
  11        12/17         \-           5/17                     \-                 Net benefit
  12        \-            2/13         1/13                     10/17              No consensus

Recommendation
--------------

The graders individual considerations about the recommendations are shown in Table [8](#T8){ref-type="table"}. During the discussion, we reached a consensus on a recommendation for the nine examples where we agreed on the balance between benefits and harms. We found that first agreeing on the balance between the benefits and harms clarified our judgements about recommendations and facilitated a consensus. There was not a one-to-one correspondence between our judgements about trade-offs and our judgements about recommendations, because the latter took into account additional considerations.

###### 

Results, summary of the recommendations made the 17 evaluators for each of the 12 examples in the pilot study

  Example   Do it   Probably do it   Toss up   Probably don\'t do it   Don\'t do it   Consensus
  --------- ------- ---------------- --------- ----------------------- -------------- ------------------------------
  1         4/16    7/16             3/16      \-                      2/16           Probably do it
  2         6/16    8/16             2/16      \-                      \-             Do it
  3         \-      6/15             7/15      2/15                    \-             Need more information
  4         13/15   2/15             \-        \-                      \-             Do it
  5         11/16   5/16             \-        \-                      \-             Do it
  6         11/17   5/17             1/17      \-                      \-             Do it
  7         1/17    7/17             2/17      6/17                    1/17           Probably do it
  8         2/15    7/15             4/15      2/15                    \-             Do it
  9         1/17    4/17             8/17      4/17                    \-             Probably don\'t do it/Tossup
  10        \-      2/17             6/17      7/17                    2/17           No consensus
  11        7/17    8/17             2/17      \-                      \-             Do it
  12        \-      \-               \-        4/13                    9/13           No consensus

Sensibility and understandability
---------------------------------

Eleven raters provided feedback on the sensibility and understandability of the GRADE system for grading evidence and formulating recommendations. Nine of the 11 respondents agreed or strongly agreed that the judgements about the overall quality of evidence were clear and understandable, and that the judgements about the balance between benefits and harms were clear and understandable using the GRADE approach. Everyone agreed or strongly agreed that the judgements about recommendations were clear and understandable. Eight of the judges agreed or strongly agreed that the GRADE approach to judging the overall quality of evidence was better than other grading systems with which they were familiar. Two disagreed and one was not sure. Eight also agreed that the GRADE approach to formulating recommendations was better than approaches with which the raters were familiar. Three raters were not sure about whether the GRADE approach was superior to other approaches of formulating recomendations.

Nine of the 11 respondents agreed or strongly agreed that the GRADE approach was applicable to different types of interventions, and that the approach was clear and simple to apply. Five judges disagreed that the information that is needed is generally available, two were not sure and four agreed. Six of the eleven judges disagreed or strongly disagreed that subjective decisions were generally not needed, four were not sure and one agreed. Ten of the eleven judges agreed or strongly agreed that all the components included in each of the four types of judgements should be included; one judge was not sure. Five of the judges were unsure if there were not important components that were missing from any of the four types of judgements, one disagreed and three agreed or strongly agreed. Eight judges agreed or strongly agreed that the ways in which the components were aggregated for each of the four types of judgements were clear and simple; three were unsure. Seven judges agreed or strongly agreed that the ways in which the included components were aggregated were appropriate for each of the four types of judgements, two were unsure and two disagree. Ten of the eleven judges agreed or strongly agreed that the categories were sufficient to discriminate between different grades for each of the four types of judgements; one disagreed. All the eleven judges agreed or strongly agreed that the GRADE approach successfully discriminated between different quality of evidence, and between different grades of recommendations.

Discussion
==========

This pilot study of the GRADE approach to grading the quality of evidence and strength of recommendations helped to identify problems with the approach and enabled us to address these. We found that it was possible to resolve most of the disagreements we had when making judgements independently and there was agreement that this approach warrants further development and evaluation.

Many of the disagreements were a direct result of a lack of information. We concluded that there is a need for detailed additional information in evidence profiles, and have modified the evidence profiles accordingly. When we have found an empirical basis or compelling arguments, we have also provided precise definitions. For example, we have agreed on a basis for defining strong and very strong associations. However, in many cases we continue to rely on judgement. We have addressed this by always including the rationale for such judgements in footnotes attached to the evidence profile.

The evidence profiles used in the pilot study were based on systematic reviews. \[[@B2]-[@B13]\] Much of the information we found lacking was missing in these original systematic reviews, particularly information about harms and side effects. It was outside of the scope of this study to systematically collect this information. However, systematic reviews of evidence of harms, as well as benefits, are essential for guidelines development panels. If reviews, such as Cochrane reviews, are going to meet the needs of guideline development panels, and others making decisions about health care, it is essential that evidence of adverse effects is systematically included in these.

An important benefit of the approach to grading evidence and recommendations that we used in this study is that it clarifies the source of true disagreements, as well as helping to resolve disagreements through discussing each type of judgement sequentially. Judgements about the relative importance of different outcomes and about trade-offs, as well as about the quality of evidence, are made explicitly, rather than implicitly. This facilitates discussion and clarification of these judgements. It may be helpful to guideline panels and others to use this approach before making decisions and recommendations.

The most common source of disagreement that we encountered was differences in what we consider to be sparse data. We have not reached a consensus on a definition of sparse data, but have acknowledged that we have different thresholds and now recognize this when we make judgements about the quality of evidence \[[@B16]\].

We have as a result of this pilot study been able to make considerable improvements to our system for grading the quality of evidence and strength of recommendations. The evidence profiles used in the pilot study have been modified and now include information that was missing and was found to be an important source of disagreement, as illustrated in Table [9](#T9){ref-type="table"} and Table [10](#T10){ref-type="table"} and the criteria used for grading the quality of evidence for each important outcome have been modified as summarised in Table [11](#T11){ref-type="table"}. Guideline generation includes judgement. Individual, residual judgements will impact on the agreement we measured in this study. Thus, lower kappa values are expected. Further refinement of the GRADE system and additional instructions will improve agreement.

###### 

Example of a modified GRADE evidence profile quality assessment. Table 9 and 10 is what Table 1 and 2 became when including the improvements made based on the pilot study experience.

Question: Should depressed patients be treated with SSRIs rather than tricyclics?

Setting: Primary care

Patients: Moderately depressed adult patients

Reference: North of England Evidence Based Guideline Development Project. Evidence based clinical practice guideline: the choice of antidepressants for depression in primary care. Newcastle upon Tyne: Centre for Health Services Research, 1997.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Outcome: **Depression severity**(measured with Hamilton Depression Rating Scale after 4 to 12 weeks)                                                                                                                                                          
  ------------------------------------------------------------------------------------------------------ -------------------- ------------------------ ---------------------------- ------------------------------------------------------- ---- ---- ---- ---- ----
  Studies                                                                                                Design               Quality                  Consistency                  Directness                                              SD   SA   RB   DR   PC

                                                                                                                                                                                                                                                                

  8 trials Citalopram\                                                                                   RCTs                 No serious limitations   No important inconsistency   Some uncertainty about directness (outcome measure)\*   No   No   No   No   No
  38 trials Fluoxetine\                                                                                                                                                                                                                                         
  25 trials Fluvoxamine\                                                                                                                                                                                                                                        
  2 trials Nefazodone\                                                                                                                                                                                                                                          
  18 trials Paroxetine\                                                                                                                                                                                                                                         
  4 trials Sertaline\                                                                                                                                                                                                                                           
  4 trials Velafaxine                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                

  Outcome: **Transient side effects resulting in discontinuation of treatment**                                                                                                                                                                                 

                                                                                                                                                                                                                                                                

  8 trials Citalopram\                                                                                   RCTs                 No serious limitations   No important inconsistency   Direct                                                  No   No   No   No   No
  50 trials Fluoxetine\                                                                                                                                                                                                                                         
  27 trials Fluvoxamine\                                                                                                                                                                                                                                        
  4 trials Nefazodone\                                                                                                                                                                                                                                          
  23 trials Paroxetine\                                                                                                                                                                                                                                         
  6 trials Sertaline\                                                                                                                                                                                                                                           
  5 trials Velafaxine                                                                                                                                                                                                                                           

                                                                                                                                                                                                                                                                

  Outcome: **Poisoning fatalities**                                                                                                                                                                                                                             

                                                                                                                                                                                                                                                                

  Office for National Statistics (British)                                                               Observational data   Serious limitation\*\*   Only one study               Direct                                                  No   ++   No   No   No
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*There was uncertainty about the directness of the outcome measure because of the short duration of the trials.

\*\*It is possible that people at lower risk were more likely to have been given SSRI\'s and it is uncertain if changing antidepressant would have deterred suicide attempts.

SD = Sparse data (Yes or No)

SA = Strong association (No, + = strong, ++ = very strong)

RB = Reporting bias (Yes or No)

DR = Dose response (Yes or No)

PC = All plausible confounders would have reduced the effect (Yes or No)

CI = confidence interval

WMD = weighted mean difference

RRR = relative risk reduction

###### 

Example of a modified GRADE evidence profile summary of findings. Table 9 and 10 is what Table 1 and 2 became when including the improvements made based on the pilot study experience

  **Outcome**                  **SSRI**                          Tricyclics                         **Effect**                    **Quality**     **Importance**   
  ---------------------------- --------------------------------- ---------------------------------- ----------------------------- --------------- ---------------- ----------
  Depression severity          5044 patients                     4510 patients                      WMD 0.034 (-0.007 to 0.075)   No difference   Moderate         Critical
  Transient side effects       1948/7032 (28%)                   2072/6334 (33%)                    RRR 13% (5% to 20%)           5 per 100       High             Critical
  Poisoning fatalities\*\*\*   1/100,000 per year of treatment   58/100,000 per year of treatment   RRR 98% (97% to 99%)          6 per 10,000    Moderate         Critical

\*\*\*There is uncertainty about the baseline risk for poisoning fatalities.

###### 

Modified GRADE quality assessment criteria

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Quality of evidence**   **Study design**         **Lower if \***                             **Higher if \***
  ------------------------- ------------------------ ------------------------------------------- --------------------------------------------------------------------------
  High                      Randomised trial         **Study quality**:\                         **Strong association**:\
                                                     -1-Serious limitations\                     +1-Strong, no plausible confounders, consistent and direct evidence\*\*\
                                                     -2-Very serious limitations\                +2-Very strong, no major threats to validity and direct evidence\*\*\*\
                                                     -1-Important **inconsistency**\             +1-Evidence of a **Dose response**gradient\
                                                     **Directness**:\                            +1-All **plausible confounders**would have reduced the effect
                                                     -1-Some uncertainty\                        
                                                     -2-Major uncertainty\                       
                                                     -1-**Sparse data**\                         
                                                     -1-High probability of **Reporting bias**   

                                                                                                 

  Moderate                  Quasi-randomised trial                                               

                                                                                                 

  Low                       Observational study                                                  

                                                                                                 

  Very low                  Any other evidence                                                   
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\* 1 = move up or down one grade (for example from high to moderate)

2 = move up or down two grades (for example from high to low)

The highest possible score is High (4) and the lowest possible score is Very low (1). Thus, for example, randomised trials with a strong association would not move up a grade.

\*\* A relative risk of \>2 (\< 0.5), based on consistent evidence from two or more observational studies, with no plausible confounders

\*\*\* A relative risk of \> 5 (\< 0.2) based on direct evidence with no major threats to validity

Judgements about confidence in evidence and recommendations are complex. The GRADE system represents our current thinking about how to reduce errors and improve communication of these complex judgements. Ongoing developments include:

• Exploring the extent to which the same system should be applied to public health and health policy decisions as well as clinical decisions

• Developing guidance for when and how costs (resource utilisation) should be considered

• Developing guidance for judgements regarding sparse data

• Adapting the approach to accommodate recommendations about diagnostic tests when these are based on evidence of test accuracy

• Incorporating considerations about equity

• Preparing tools to support the application of the GRADE system

Plans for further development include studies of the reliability and sensibility of this approach and a study comparing alternative ways of presenting these judgements \[[@B17]\]. We invite other organisations responsible for systematic reviews of the effects of healthcare or practice guidelines to work with us to further develop and evaluate the system described here.

Conclusion
==========

Based on the results of this pilot study we have been able to considerably improve our system for grading the quality of evidence and strength of recommendation \[[@B16]\].
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